| Date Filed | Type | Description |
| 08/02/2023 |
4
| Lee Chan Henry (SVP, General Counsel) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 791 shares
@ $216.2567, valued at
$171.1k
|
|
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
8-K
| Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive ... |
| 07/06/2023 |
4
| Wang Julia Aijun (CFO) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 472 shares
@ $179.5495, valued at
$84.7k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/15/2023 |
4
| HHLR ADVISORS, LTD. (10% Owner) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 611,000 shares
@ $211.4522, valued at
$129.2M
Sold 313,400 shares
@ $128.4335, valued at
$40.3M
Sold 273,728 shares
@ $207.7171, valued at
$56.9M
|
|
| 06/12/2023 |
4
| HHLR ADVISORS, LTD. (10% Owner) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 1,163,825 shares
@ $218.1443, valued at
$253.9M
Sold 213,700 shares
@ $130.3523, valued at
$27.9M
Sold 328,952 shares
@ $217.0183, valued at
$71.4M
Sold 281,400 shares
@ $130.8322, valued at
$36.8M
Sold 968,812 shares
@ $213.9125, valued at
$207.2M
|
|
| 06/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
4
| Wang Lai (Global Head of R&D) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 74 shares
@ $223.2333, valued at
$16.5k
Sold 161 shares
@ $224.0403, valued at
$36.1k
Sold 111 shares
@ $225.2721, valued at
$25k
Sold 116 shares
@ $226.1511, valued at
$26.2k
|
|
| 06/09/2023 |
4
| Wu Xiaobin (President, COO & GM China) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 531 shares
@ $223.2333, valued at
$118.5k
Sold 1,147 shares
@ $224.0403, valued at
$257k
Sold 789 shares
@ $225.2721, valued at
$177.7k
Sold 824 shares
@ $226.1511, valued at
$186.3k
|
|
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/26/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
4
| Wu Xiaobin (President, COO & GM China) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 7,000 shares
@ $253.7196, valued at
$1.8M
|
|
| 05/09/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/09/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/10/2023 |
4
| Wang Xiaodong (Director) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Exercised 67,635 shares
@ $0.13, valued at
$8.8k
Sold 3,433 shares
@ $222.9985, valued at
$765.6k
Sold 7,458 shares
@ $224.0088, valued at
$1.7M
Sold 12,534 shares
@ $224.9239, valued at
$2.8M
Sold 400 shares
@ $225.3475, valued at
$90.1k
Sold 200 shares
@ $226.6109, valued at
$45.3k
Sold 14,077 shares
@ $225.9541, valued at
$3.2M
Sold 17,170 shares
@ $227.1205, valued at
$3.9M
Sold 12,363 shares
@ $227.7809, valued at
$2.8M
Exercised 879,255 options to buy
@ $0.01, valued at
$8.8k
|
|
| 02/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
8-K
| Quarterly results |
|